<DOC>
	<DOCNO>NCT01575535</DOCNO>
	<brief_summary>RATIONALE : Studying sample bone marrow patient cancer laboratory may help doctor identify learn biomarkers related cancer . PURPOSE : This research trial study bone marrow sample woman acute myeloid leukemia .</brief_summary>
	<brief_title>S0106B Studying Bone Marrow Samples From Women With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Estimate proportion acute myeloid leukemia ( AMLs ) originate CD33+ precursor uncontrolled growth limited CD33+ precursor . - Explore whether association cellular origin AML ( i.e. , origination CD33+ precursor ) cytogenetic , molecular , patient characteristic . - Explore whether overall survival ( OS ) , event-free survival ( EFS ) , disease-free survival ( DFS ) , response rate ( RR ) , relapse rate improve patient AMLs originate CD33+ precursor uncontrolled growth limited CD33+ precursor compare patient clonally involved cell detect . OUTLINE : Archived bone marrow sample analyze CD33+ progenitor , X-chromosome inactivation , somatic mutation ( ( 8 ; 21 ) , inv ( 16 ) , FLT3/ITD , NPM1 , CEBPA , KIT ) fluorescence-activated cell sorting , long-term culture hypoxic condition cytokine-containing liquid medium , flow cytometry . Results compare patient clinical data .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnostic bone marrow specimen female patient untreated AML undergo intensive ( `` 3+7 '' like ) induction chemotherapy Specimens South Western Oncology Group ( SWOG ) protocols S0106 ( age 18 60 year ) , exclude patient receive gemtuzumab ozogamicin ( GO ) , S9333 ( age &gt; 60 year ) PATIENT CHARACTERISTICS : See Disease Characteristics PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia del ( 5q )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
</DOC>